Albinism
13
4
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
7.7%
1 terminated out of 13 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
FARD (RaDiCo Cohort) (RaDiCo-FARD)
Implementation of Long-read Sequencing for the Diagnosis of Rare Diseases.
Genetic Analysis and Multimodal Retinal Imaging of Asymptomatic Fovea Plana Cases in the General Population
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Reproductive Options in Inherited Skin Diseases
Functional Tests to Resolve Unsolved Rare Diseases. Rares.
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
Vision Response to Dopamine Replacement
Nitisinone for Type 1B Oculocutaneous Albinism
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Visual Function and Ocular Pigmentation in Albinism